1
Preclinical research shows that the combination of two existing drugs can exploit the metabolic’hunger’ of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue.
Preclinical research shows that the combination of two existing drugs can exploit the metabolic’hunger’ of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue.